Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

[1]  C. Parker,et al.  Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. , 2016, European urology.

[2]  S. Ramsey,et al.  The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. , 2016, The oncologist.

[3]  C. Parker,et al.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  C. Mullins,et al.  Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods , 2015, BMC Medical Research Methodology.

[5]  C. Parker,et al.  673 Effects of radium-223 dichloride (Ra-223) on health-related quality of life (HRQoL) assessed by the EQ-5D utility scores in ALSYMPCA , 2015 .

[6]  M. Menon,et al.  The burden of skeletal-related events in patients with prostate cancer and bone metastasis. , 2015, Urologic oncology.

[7]  J. Reuning-Scherer,et al.  Effects of radium-223 dichloride (Ra-223) on risk for hospitalization and health care resource use in the phase 3 ALSYMPCA trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Lorusso,et al.  Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study , 2014, Journal of clinical medicine.

[9]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[10]  C. Mullins,et al.  The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer , 2014, PharmacoEconomics.

[11]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[12]  T. Delea,et al.  Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases , 2012, Prostate Cancer and Prostatic Diseases.

[13]  D. Castellano,et al.  The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain , 2010, European journal of cancer care.

[14]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.